Cephalexin or Co-amoxiclav for Impetigo
For impetigo, both cephalexin and co-amoxiclav (amoxicillin-clavulanate) are equally acceptable first-line oral antibiotics when systemic therapy is indicated. The 2024 WHO Essential Medicines guidelines list both as first-choice agents (Access category) for mild skin and soft tissue infections, including impetigo 1. The 2014 IDSA guidelines similarly list both agents with identical dosing recommendations for impetigo treatment 2.
When to Choose Each Agent
Choose Cephalexin When:
- Standard impetigo cases caused by Staphylococcus aureus and Streptococcus pyogenes 2
- Narrower spectrum preferred for antimicrobial stewardship purposes
- Cost considerations matter (typically less expensive)
- Patient has no penicillin allergy concerns
Dosing:
Choose Co-amoxiclav When:
- Broader coverage needed for polymicrobial or uncertain etiology
- Treatment failures with narrower-spectrum agents
- Local resistance patterns favor beta-lactamase coverage
Dosing:
Important Clinical Context
Topical therapy should be considered first for limited disease. Mupirocin 2% or retapamulin 1% ointment are recommended initial treatments for mild, nonbullous and bullous impetigo with limited lesions 3, 4. Oral antibiotics are reserved for:
- Extensive/multilesional disease
- Failure of topical therapy within 3-5 days
- Outbreak situations requiring rapid control 3
Key Caveats
Avoid penicillin V - it is seldom effective for impetigo and should not be used 5. Both S. aureus and S. pyogenes are the causative organisms, and penicillin V lacks adequate staphylococcal coverage.
Monitor for MRSA - If treatment fails after 3-5 days, consider community-acquired MRSA and switch to agents like clindamycin, trimethoprim-sulfamethoxazole, or doxycycline (in patients >8 years) 2, 4.
Erythromycin resistance is rising and this agent should be avoided unless susceptibility is confirmed 2, 4.
Treatment duration is typically 7 days, though clinical improvement should be evident within 3-5 days 3.
Practical Considerations
Both cephalexin and co-amoxiclav have FDA approval for skin and skin structure infections caused by susceptible organisms 6. The choice between them is clinically equivalent based on guideline evidence, so default to cephalexin for its narrower spectrum unless specific circumstances favor broader coverage 1, 2.